Rallybio (RLYB) AI Stock Analysis

• Market Cap: $23.78M
• Dividend Yield: N/A
• Average Volume (3M): 653.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.91
• Revenue Growth: 154.52%
• EPS Growth: 47.84%
• Country: US
• Employees: 25
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.22
• Shares Outstanding: 41,786,472
• 10 Day Avg. Volume: 457,747
• 30 Day Avg. Volume: 653,975
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -1.28
• Enterprise Value/Revenue: -40.12
• Enterprise Value/Gross Profit: -41.77
• Enterprise Value/Ebitda: 0.71
• 1Y Price Target: $1.00
• Price Target Upside: 69.49% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 35 Underperform
• Price Target: ―

Rallybio's stock is under significant pressure due to poor financial performance characterized by operational losses and negative cash flows, compounded by bearish technical indicators and challenging valuation metrics. Without revenue growth, the sustainability of operations is at risk, making it a highly speculative investment in its current state.

Positive Factors

Financial Performance

The recent workforce reduction plan and sale of REV102 interest should provide cash runway into mid-2027.

Investment Potential

Phase 1 data for differentiated C5 inhibitor RLYB116 could draw investor interest back to RLYB.

Pipeline Advancement

Rallybio will now focus its resources on advancing other pipeline programs, notably RLYB116, an inhibitor of complement component 5 (C5) with potential applications in treating complement-related diseases.

Negative Factors

Clinical Trial Setback

The decision to discontinue RLYB212 was based on pharmacokinetic (PK) data from the Phase 2 trial indicating the inability to achieve predicted target concentrations, as well as the minimum target concentration required for efficacy.

Program Discontinuation

Rallybio has announced the discontinuation of its RLYB212 program, which was undergoing development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Stock Valuation Concerns

RLYB shares were already trading at a steep discount to its cash balance before the discontinuation of RLYB212.

Rallybio Business Overview & Revenue Model

Company Description

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

How the Company Makes Money

Rallybio makes money through the development and commercialization of its proprietary drug candidates. Revenue is primarily generated from partnerships and collaborations with larger pharmaceutical companies, which may include milestone payments, royalties, and licensing fees. Additionally, the company may receive funding from grants and research agreements to support its clinical trials and product development efforts. As Rallybio advances its pipeline products through clinical trials and towards regulatory approval, it aims to establish further commercial agreements to drive revenue growth.

Rallybio Financial Statement Overview

Summary

Rallybio's financials indicate significant challenges, with high operational losses and a negative cash flow situation typical for a biotech in the R&D phase. The firm relies heavily on equity financing, and the lack of revenue growth poses sustainability risks.

Income Statement

Rallybio's income statement reveals significant challenges, with high negative EBIT and net income figures, indicating substantial losses. The gross profit margin is theoretically 100% due to low revenue but masks the underlying operational losses. The company has shown no revenue growth, reflecting the R&D stage typical in biotech, yet this poses sustainability concerns.

Balance Sheet

The balance sheet shows a strong equity base relative to liabilities, with a high equity ratio due to minimal debt. However, the substantial and consistent net losses are eroding equity, with return on equity being severely negative, indicating inefficient use of equity capital.

Cash Flow

Rallybio's cash flow statement highlights a concerning trend of negative operating and free cash flows, indicating cash burn typical for a biotech firm in development phases. The positive but declining cash position from financing activities raises sustainability questions without revenue growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	761.00K	636.00K	0.00	0.00	0.00	0.00
Gross Profit	731.00K	636.00K	-150.00K	-167.00K	-109.00K	-62.03K
EBITDA	-43.31M	-60.50M	-72.37M	-65.41M	-45.39M	-24.83M
Net Income	-41.65M	-57.77M	-74.56M	-66.49M	-47.01M	-26.45M
Balance Sheet
Total Assets	51.00M	68.11M	115.62M	180.44M	182.19M	141.86M
Cash, Cash Equivalents and Short-Term Investments	45.75M	65.51M	109.93M	168.99M	175.33M	140.23M
Total Debt	58.00K	154.00K	392.00K	555.00K	0.00	0.00
Total Liabilities	5.04M	6.45M	9.44M	11.12M	6.58M	5.86M
Stockholders Equity	45.96M	61.65M	106.18M	169.32M	175.60M	136.00M
Cash Flow
Free Cash Flow	-41.99M	-49.28M	-60.28M	-57.34M	-45.87M	-22.18M
Operating Cash Flow	-41.99M	-49.28M	-60.27M	-57.28M	-45.53M	-22.04M
Investing Cash Flow	34.75M	33.49M	27.66M	-112.17M	-2.33M	-2.07M
Financing Cash Flow	17.00K	5.20M	143.00K	51.08M	82.97M	144.89M

Rallybio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.59
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RLYB, the sentiment is Positive. The current price of 0.59 is above the 20-day moving average (MA) of 0.53, above the 50-day MA of 0.45, and below the 200-day MA of 0.64, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 60.09 is Neutral, neither overbought nor oversold. The STOCH value of 77.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RLYB.

Rallybio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADXN	58 Neutral	$13.37M	0.70	-162.42%	―	-82.24%	―
Sector *	51 Neutral	$7.77B	-0.12	-39.78%	2.21%	22.68%	-1.42%
MBRX	44 Neutral	$18.05M	―	-503.80%	―	―	60.64%
MRKR	44 Neutral	$14.62M	―	-144.68%	―	44.55%	-17.92%
RLYB	35 Underperform	$23.78M	―	-66.12%	―	154.52%	47.84%
NERV	34 Underperform	$16.02M	1.55	>-0.01%	―	―	―
ICU	33 Underperform	$22.33M	―	1475.93%	―	―	87.87%